(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 15.84% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.73%.
Neuropace's revenue in 2026 is $99,530,000.On average, 10 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,457,446,680, with the lowest NPCE revenue forecast at $3,274,363,270, and the highest NPCE revenue forecast at $3,600,981,347. On average, 10 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,277,401,248, with the lowest NPCE revenue forecast at $3,862,480,371, and the highest NPCE revenue forecast at $4,570,607,455.
In 2028, NPCE is forecast to generate $5,324,761,094 in revenue, with the lowest revenue forecast at $4,861,427,100 and the highest revenue forecast at $5,727,749,160.